MiR-489 aggravates H$_2$O$_2$-induced apoptosis of cardiomyocytes via inhibiting IGF1

Shan Tang $^a$, Hongyan Zhong $^b$, Ting Xiong $^a$, Xinquan Yang $^a$, Yongqing Mao $^a$, and Daxin Wang $^b$

a The Second Xiangya Hospital of Central South University, Changsha, China.
b Clinical Medical College, Yangzhou University, Yangzhou, China.

*Corresponding author: Daxin Wang(DaxinWang_2019@126.com), Clinical Medical College, Yangzhou University, 88# South University Ave, Yangzhou, Jiangsu, 225009, China.
ABSTRACT

Myocardial infarction (MI) is a major type of cardiovascular disorder worldwide. In this study, we established a new microRNA (miRNA)-mRNA crosstalk network by integrating data obtained from The National Center for Biotechnology Information Gene Expression Omnibus (NCBI GEO). In addition, functional assays, including Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and Gene Ontology (GO) analyses, were conducted using the Database for Annotation, Visualization, and Integration Discovery (DAVID). In our study, we generated a new differentially expressed miRNA (DEmiRNA)-differentially expressed gene (DEG) crosstalk network of MI composed of 3 miRNA (miR-489, miR-375, and miR-142-3p) nodes and 163 mRNA nodes. In vitro experiments demonstrated that miR-489 expression was increased in H2O2-treated H9c2 cardiomyocytes in vitro, mimicking myocardial injury. We observed that downregulation of miR-489 reduced H2O2-induced apoptosis, while overexpression of miR-489 had the opposite effects, as revealed by flow cytometry and Western blot analyses. Furthermore, we confirmed the relationship between miR-489 and IGF1 through double luciferase reporter gene assays, which partly explains the antiapoptotic mechanism of miR-489. In conclusion, the experimental results of this study could provide important clues for investigating the mechanism of MI.

Keywords:

Myocardial infarction; miR-489; IGF1; H9c2; Bioinformatics.
1. Introduction

Myocardial infarction (MI) is a common and catastrophic cardiovascular disorder characterized by myocardial necrosis induced by long-term ischemia [1]. Acute MI (AMI) is the primary cause of cardiovascular disorders and is a highly common cause of mortality and disability [2]. Nearly 550,000 first-episode and 200,000 recurrent AMIs occur each year, causing major social and economic burdens on healthcare systems [3]. In the clinic, the diagnosis and treatment of AMI is primarily based on clinical symptoms.

At present, the clinical treatment of acute myocardial infarction primarily involves the recanalization of large blood vessels, which results in myocardial ischemia-reperfusion injury. There has been a great deal of work to elucidate the cause of such injuries, but reperfusion injury is still unavoidable once revascularization is performed[4,5,6].

Currently, although extensive efforts have been made to elucidate the molecular mechanisms that contribute to AMI [7,8,9,10], the etiology and pathogenesis of this condition remains unclear. Therefore, there is an urgent need to identify biomarkers and mechanisms for this condition for the prediction and treatment of MI.

MicroRNAs (miRNAs) are a type of small noncoding RNAs with fewer than 22 nucleotides that negatively regulate transcription by inhibiting protein translation or degradation. Increasing numbers of studies have shown that abnormal miRNA expression can lead to various cardiovascular disorders, including cardiac ischemia and vascular atherosclerosis [11,12]. For example, miR-342-5p in circulating exosomes induced by long-term exercise can have an endogenous cardioprotective role in
myocardial ischemia/reperfusion injury by inhibiting hypoxia/reoxygenation-induced cardiomyocyte apoptosis by targeting caspase 9 and Jnk2 and activating p-Akt signaling through regulation of Ppm1f [13].

The role of bioarray techniques in basic research has been increasingly recognized by scientists, as it allows for the identification of new genes and noncoding RNAs linked to multiple diseases, providing potential clues and scientific evidence for further studies using bioinformatics tools [14]. In the present study, the gene expression profile of GSE34198 and the miRNA expression profiles of GSE61741 and GSE31568 were obtained from the Gene Expression Omnibus (GEO) [15,16,17]. The limma package and metaMA package in R were used to identify differentially expressed (DE) genes (DEGs) and DE miRNAs (DEmiRNAs) of MI, respectively. Enrichment analyses were conducted to elucidate the functions of the DEGs in MI. We constructed a protein-protein interaction (PPI) network of the DEGs and defined the genes with a high values in the network as hub genes. We predicted the target genes of DEmiRNAs by searching the miRWalk database and establishing a new miRNA-mRNA regulatory network that is involved in the development and occurrence of MI; these findings will provide new insights for the diagnosis and treatment of MI.

We identified several DEmiRNAs associated with MI, including miR-489, miR-1274b, miR-142-3p, and miR-375. The results of a previous study proved that inhibition of both endothelial miR-92a and miR-489 can reduce chronic kidney disease-associated atherosclerosis, repressing the elevated expression of Fam220a and
Tgfb2, respectively [18]. In a rat model of gentamicin injury, elevation of miR-489 in urine preceded elevation of urinary creatinine and blood urea nitrogen, suggesting that urinary miR-489 could be a new biomarker of kidney injury [19]. Interestingly, intrarenal miR-489 and urinary miR-489 were both elevated in a kidney model of ischemia-reperfusion injury [20]. Previous research has shown that extracellular and cellular levels of miR-489-3p are related to cardiovascular and kidney disorders, but the function, mechanism and therapeutic potential of miR-489-3p in MI have not been reported. Therefore, this study, we generated an in vitro MI model using H9c2 cardiomyocytes to assess MI and verify the effects of miR-489 in myocardial damage.

2. Materials and methods

Gene expression profile data

The gene expression profiles of GSE34198 and the miRNA expression profiles of GSE61741 and GSE31568 were obtained from the GEO database. In these GSEs, 10 samples were randomly selected for differential expression analysis.

Screening for DEGs and DEmiRNAs

The DEGs were identified using an empirical Bayesian method through the R “limma” package. The threshold of DEGs was defined with |logFC| > 1 and P-value < 0.05. In addition, the metaMA package, which can handle missing data and eliminate batch effects, was used to integrate the different platforms [21]. We used the limma and metaMA packages to confirm the DEmiRNAs, and |ES| > 6 and FDR < 0.05 was used to filter the identified DEmiRNAs.

Functional enrichment analysis of DEGs
To annotate the genes and identify characteristic biological attributes for these DEGs, we performed Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and Gene Ontology (GO) analyses with the Database for Annotation, Visualization and Integrated Discovery (DAVID). Each item of enrichment had a cut-off criterion of $P < 0.05$.

**Construction of a PPI network**

To uncover the core regulatory genes, we used the STRING database [22] to construct a PPI network. These interaction networks were visualized using Cytoscape [23].

**Prediction of target genes of DEmiRNAs**

To predict targets of DEmiRNAs, we used the online database miRWalk. In addition, to screen for predicted target genes, we constructed a regulatory network between DEmiRNAs and DEGs.

**H9c2 cell culture and treatment**

Mouse H9c2 cardiomyocytes (Chinese Academy of Sciences, Shanghai, China) were cultured at 37°C in a humidified incubator under an atmosphere with 5% CO$_2$ in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum (Gibco, USA), 100 units/mL penicillin, and 100 μg/mL streptomycin (Suo Lai Bao Biotechnology Co., Ltd., Beijing, China). To establish the in vitro model of MI, we seeded cells in 6-well plates at a density of $1 \times 10^5$ cells/well and treated them with 0, 100, 200, 400, 450, and 500 μM H$_2$O$_2$ for 1 h, with 450 μM selected for analysis in the subsequent experiments.
H9c2 cell transfection

To perform gain- and loss-of-function analyses, we seeded H9c2 cells in 6-well plates and performed transfections when the cells are at logarithmic growth period. In addition, under good cell growth conditions, the cells exhibited a strong refractive property, a plump cytoplasm and a clear nuclear cytoplasm under a microscope. The cells were transfected with 50 nM miR-489 mimic and 100 nM miR-489 inhibitor or miRNA-inhibitor negative control (NC) (RiboBio, China) using RiboFECT™ CP reagent (RiboBio, China) following the manufacturer’s instructions. Protein and RNA extraction was performed after 48 h.

Cell Counting Kit-8 (CCK8) assays

Cell viability was examined by CCK8 (Dojindo, Japan) assays. We seeded 100 μL of cell suspension per well into 96-well plates at a density of 5000 cells/well. At specific time points, we added 10 μL of CCK-8 solution to the cells and incubated the samples for 2 h at 37°C. Then, the reaction product was quantified following the manufacturer’s instructions.

Western blot analysis

H9c2 cell extracts were prepared in RIPA lysis buffer (Suo Lai Bao, Beijing, China) containing 1% phenylmethanesulfonyl fluoride (PMSF). Total proteins were quantified with a BCA protein assay kit (Vazyme, China). The proteins were electrophoresed in sodium dodecyl sulfate (SDS)-polyacrylamide gels and then transferred to PVDF membranes (Millipore, MA, USA). The membranes were incubated for 2 h with 5% nonfat milk in Tris-buffered saline for blocking. Subsequently, the membranes were
incubated overnight at 4°C with the following primary antibodies: anti-caspase-3 (1:1000, Proteintech, 19677-1-AP), anti-Bcl-2 (1:1000, Proteintech, 26593-1-AP), anti-BAX (1:1000, Proteintech, 50599-2-Ig), anti-IGF1 (1:1000, Abelonal, Huohao), and anti-β-actin (1:5000, Sigma, A2228). Then, the membranes were incubated with the appropriate secondary antibodies for 2 h on a shaker at room temperature. The protein levels were quantified by relative densitometry and normalized to that of β-actin as an internal control.

RNA extraction and RT-qPCR

The miR-489 levels in H9c2 cells were measured using RT-qPCR. After H2O2 treatment, the total RNA of the samples was extracted using TRIzol reagent (Tiangen, China), after which 1 μg of RNA was used to synthesize cDNA using a RevertAid First Strand cDNA Synthesis kit (Thermo Fisher Scientific, USA). Gene expression was assessed with Genious 2× SYBR Green Fast qPCR Mix (High ROX Premixed) (ABclonal, China).

MiR-489 primers: F: 5’-CCGCCATGACATCATATATG-3’, R: 5’-CAGTG CGTGTGTGGAGT-3’, and RT: 5’-GTCGTATCCAGTGCAGTGCTGGAGTC GGCAATTGACACTGGACGCTGCA-3’; and U6 primers: F: 5’-CTCG CTTCGGCAGCACA-3’, R: 5’-AACGCTTCACGAATTTCGCT-3’ and RT: 5’- AACGCTTCACGAATTGCGT-3’.

TUNEL assay

The apoptosis of H9c2 cells was assessed using a one-step TUNEL assay kit (KeyGen, Nanjing, China). After being fixed with 2% formaldehyde and permeabilized on ice
with 0.1% Triton X-100, samples were then incubated at 37°C with TUNEL reaction buffer according to the manufacturer’s protocol. Subsequently, fluorescence microscopy was used to observe the apoptotic cells.

**Cell apoptosis analysis**

The apoptosis rate of cells was evaluated using an Apoptosis Detection Kit (Vazyme Biotech) following the manufacturer’s instructions. The apoptotic rate was obtained by calculating the sum of the ratio of the right upper quadrant and the right lower quadrant.

**Double luciferase reporter gene assay**

The binding domain of miR-489 and the 3’ untranslated region (UTR) of IGF1 was obtained from the online database miRWalk. The 3’-UTRs of IGF1 with wild-type and mutant binding sites for miR-489 were generated by RiboBio (Guangzhou, China) and cloned into pmiR-RB-REPORT (RiboBio). The vectors were cotransfected with miR-489 mimic and control into 293T cells, after which the cells were incubated for 48 h and then analyzed for luciferase activity. Next, the Dual-Glo® Luciferase Assay System (Promega, Madison, USA) was used to calculate the relative luciferase activity following the manufacturer’s protocol.

**Statistical analysis**

The results are presented as the means ± SEM. Statistical comparisons among different groups were conducted by one-way ANOVA, while differences between two groups were assessed by Student’s t-test. P < 0.05 was defined as significant.

### 3. Results
Screening for DEGs

We identified 688 DEGs (including 500 upregulated genes and 188 downregulated genes) from the gene expression datasets (criteria of \( P < 0.05 \) and \( |\log FC| \geq 1 \)). In addition, we obtained 4 DEmiRNAs based on \(|\text{combined ES}| > 6\) and FDR < 0.05 using the metaMA package and the miRNA expression dataset. The top 10 DEGs and DEmiRNAs are shown in Tables S1 and S2, respectively.

Functional analysis results

DAVID was used for GO functional analysis and KEGG pathway enrichment analysis. The GO analysis results indicated that the DEGs were primarily enriched in “histone acetyltransferase activity”, “positive regulation of transcription from RNA polymerase II promoter”, and “signal transduction involved in regulation of gene expression” (Table S3). The primary KEGG pathways were “Cytokine-cytokine receptor interaction”, “Glycosphingolipid biosynthesis - lacto and neolacto series”, and “Intestinal immune network for IgA production” (Table S3).

Hub genes in the PPI network

As shown in Fig. 1A, 157 DEGs (125 upregulated and 32 downregulated genes) containing 157 nodes and 256 edges were present in the PPI network. Since the key nodes could have important roles in biological networks, we calculated all the node values in the PPI network. The top ten candidates were IL6, estrogen receptor 1 (ESR1), ACTR3, NDC80, RANBP2, CDC5L, IGF1, MCTS1, IL7R, and YWHAG.

Construction of a DEmiRNA-DEG crosstalk network

First, the targets of three DEmiRNAs were predicted from the miRWalk database,
after which the target genes and the DEGs were compared, and 136 DE target genes were obtained. Finally, a new MI-related DEmiRNA-DEG regulatory network with 139 nodes and 236 edges was constructed and shown in Fig. 1B.

MiR-489 is upregulated in H2O2-induced H9c2 cells

The viability of H2O2-treated H9c2 cells was assessed using a CCK8 kit. Cell viability decreased in dose-dependent manner and reached approximately 50% at 450 μm H2O2 (Fig. 2A). Therefore, we cultured H9c2 cells in 450 μm H2O2 for 1 h to simulate hypoxia induced by MI in vitro. As shown in Fig. 2B, the levels of proapoptotic proteins (cleaved caspase3 and Bax) were increased, whereas that of the anti-apoptotic protein Bcl-2 was decreased, demonstrating that H2O2 triggered cell injury. The RT-qPCR results effectively showed miR-489 expression in cardiomyocytes under normal or H2O2 conditions. As shown in Fig. 2C, miR-489 expression was increased in H9c2 cardiomyocytes treated with H2O2 compared to those cultured under normal conditions (P < 0.05), suggesting that miR-489 may be involved in mediating H2O2-induced H9c2 cell damage.

MiR-489 regulates H2O2-induced H9c2 cell apoptosis in vitro

To further elucidate the effect of miR-489 on H2O2-induced apoptosis, we silenced miR-489 with miRNA inhibitors. Fig. 3A shows that miR-489 expression in the miR-489 inhibitor group was lower than that observed in the NC group (P < 0.05). The results of Tunel assays (Fig. 3B), flow cytometry (Fig. 3C) and Western blot analyses to detect the expression of apoptosis-related proteins (Fig. 3D), including Bax, Bcl-2 and cleaved caspase 3, revealed that miR-489 downregulation decreased H2O2-induced
apoptosis.

**MiR-489 inhibits the expression IGF1 in H$_2$O$_2$-treated H9c2 cells**

To investigate the effect of miR-489 on H$_2$O$_2$-induced apoptosis, we used miRWalk to predict candidate targets of miR-489 in H9c2 cells. The predicted binding site of the IGF1 3'-UTR and the complementary sequence of miR-489 are shown in Fig. 4A. Furthermore, our hypothesis was confirmed by dual luciferase reporter assays. As shown in Fig. 4B, the luciferase activity notably decreased after cotransfection with the miR-489 mimic and pGL3-IGF1-wt vector. In contrast, this result was not observed in the group transfected with pGL3-IGF1-mut. Our experimental data showed that miR-489 may participate in H$_2$O$_2$-induced cardiomyocyte apoptosis by regulating IGF1. In addition, as shown in Fig. 4C, the IGF1 protein level decreased after H9c2 cells were treated with H$_2$O$_2$. In H9c2 cells treated with H$_2$O$_2$ and the miR-489 inhibitor, the IGF1 level increased compared to that observed in the H$_2$O$_2$ group. These findings indicate that IGF1 may be a target of miR-489.

**4. Discussion**

An increasing number of basic and clinical studies have uncovered the possible mechanisms underlying the development and progression of MI in the past decades. However, the pathogenesis of MI has not been fully elucidated, and crucial molecular mechanisms involved in MI need to be further investigated. In this study, mRNA and miRNA expression profile datasets were used to identify DEGs and DEmiRNAs potentially involved in MI. In total, 688 DEGs (including 500 upregulated and 188 downregulated mRNAs) and 4 DEmiRs (including 1 upregulated and 3 downregulated
miRNAs) were identified.

In the DEmiRNA-DEG regulatory network, miR-489 may participate in the pathology of MI by regulating IGF1 expression. We used the DAVID database to analyze the function of DEGs, resulting in 10 hub genes with high values (IL6, ESR1, ACTR3, NDC80, RANBP2, CDC5L, IGF1, MCTS1, IL7R, and YWHAG) being identified from the PPI network. These results identified important genes involved in the molecular mechanism of MI initiation and progression, which may be useful for the development of novel treatment strategies.

In the current study, many DE RNAs had a high values in the PPI network, suggesting that they may have important roles in the pathogenesis of MI. Various previous studies have proven that the abnormal expression of ESR1, which had the highest value in our PPI network, was closely associated with cardiovascular diseases. Dysfunction of ESR1 may be one of the causes of acute coronary events [24]. In a previous study, female mice overexpressing ERα underwent LAD coronary ligation followed by reperfusion, and the myocardial fibrosis of the mouse heart muscle was relieved, indicating that ERα could protect against ischemic injury in the hearts of female rodents [25]. A study by Zhai et al. showed that ERα could protect male mice from ischemia/reperfusion (I/R) injury and that ERα knockout may aggravate I/R damage by impeding the calcium influx and disrupting the mitochondrial function [26]. In an I/R injury model of adult female rabbits, acute pretreatment with estrogen or an Erα activator substantially reduced the area of infarction, indicating that estrogen may exert a protective role during I/R through the ER [27]. Furthermore, ERα was shown
to play protective roles in the female heart by regulating the activation of p38 MAPK, proapoptotic signaling and the expression of proinflammatory cytokines [28]. The results of these studies suggested that regulation of ESR1 could be a possible strategy for the treatment of MI.

In this study, a functional analysis of the 688 identified DEGs showed that they were enriched in various cellular functions, especially histone acetyltransferase activity, the Wnt signaling pathway and other functions.

This finding suggests that the alterations of cardiomyocyte metabolism could have important roles in MI. The reinitiation of blood flow after myocardial ischemia could lead to additional injury to cardiomyocytes, potentially causing MI and heart failure by inducing oxidative stress [29]. The oxidative stress response of cardiomyocytes may be regulated by lysine acetylation. In a rat myocardial I/R model, HDAC6 could deacetylate peroxiredoxin 1 and reduce its activity, increasing ROS production and exacerbating oxidative damage in cardiomyocytes [30].

Moreover, alteration of lysine acetylation was shown to be associated with the development of cardiovascular diseases, including hypertension [31,32,33,34], coronary artery disease [35], vascular calcification [36], and heart failure [37]. Additionally, the Wnt pathway inhibitor DKK-1 was shown to relieve atherosclerosis by affecting the proliferation of vascular smooth muscle cells (VSMCs) cultured in hyperlipidemic serum [38]. When N-cadherin was overexpressed, inhibition of classical Wnt signaling could reduce VSMC proliferation by 50% [39]. Kaga et al. observed that intracellular β-catenin was aggregated after the addition of the GSK-3β
inhibitor lithium, resulting in decreased cardiomyocyte and vascular endothelial cell apoptosis [40]. In another study, Wnt11 expression was shown to improve the survival of MI and cardiac function by suppressing inflammatory cytokine expression through regulation of NF-κB [41]. Overall, these studies demonstrated that histone acetyltransferase activity and the Wnt signaling pathway have crucial roles in the occurrence and development of MI.

Cytokine-cytokine receptor interactions are associated with health and are important during immunological and inflammatory responses in disease conditions. To establish a new regulatory network related to MI and to discover new molecular mechanisms, we built a DEmiRNA-DEG regulatory network. The network suggested that miR-489 may have important roles by regulating IGF1 in the pathological and physiological processes of MI.

Our experiments also showed that the expression of miR-489 was increased in cardiomyocytes treated with H2O2, suggesting that miR-489 may be involved in H9c2 cell apoptosis induced by H2O2. Consequently, inhibition of miR-489 expression may be a possible therapeutic approach to prevent MI. To further explore the functional and molecular mechanisms of miR-489, we used bioinformatics analysis to predict the potential targets of miR-489 and performed luciferase reporter assays to verify the relationship between these molecules.

In our study, IGF1 expression was reduced in H2O2-induced H9c2 cells, which contrasted with that observed for miR-489. We proved that miR-489 directly binds to the 3’-UTR of IGF1 to inhibit the expression of IGF1. Furthermore, according to
previous studies, IGF1 promotes heart survival, which may accelerate protein metabolism, promote cardiomyocyte growth and regulate myocardial contraction, while inhibiting apoptosis during cardiac ischemia [42]. Clinical studies have shown that low IGF1 levels may be positively associated with all-cause mortality and recurrence of MI [43]. In addition, IGF1 may have a protective effect on the heart in animal models [44]. Thus, our experimental data are consistent with those of previous studies showing that the reduction of IGF1 may be associated with myocardial injury.

In summary, our data showed that miR-489 may be a cardiomyocyte injury factor in MI. First, our results demonstrated that miR-489 expression is increased in H₂O₂-treated H9c2 cells. Moreover, miR-489 could regulate apoptosis by targeting IGF1 in myocardial cells. Taken together, these results indicate that miR-489 is a potential therapeutic target for myocardial injury and that IGF1 may be a potential novel myocardial protective factor.

Acknowledgements

Not applicable.

Funding

This work was supported by grants from “Six talent peaks project” in Jiangsu Province (2014-SWYY-052) and Jiangsu Provincial “333 Engineering” (BRA2015171).

Authorship

Daxin Wang conceived and designed the study and gave final approval of manuscript. Shan Tang contributed to experiments and manuscript writing. Hongyan Zhong, Ting
Xiong, Xinquan Yang and Yongqing Mao contributed to the conception and design of experiments and performed data analysis.

**Ethics approval and consent to participate**

Not applicable.

**Patient consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**References**

[1] G.W. Reed, J.E. Rossi, C.P. Cannon, Acute myocardial infarction, The Lancet 389 (2017) 197-210.
[2] K. Thygesen, J.S. Alpert, A.S. Jaffe, M.L. Simoons, B.R. Chaitman, H.D. White, Third universal definition of myocardial infarction, Circulation 126 (2012) 2020-2035.
[3] D. Mozaffarian, E.J. Benjamin, A.S. Go, D.K. Arnett, M.J. Blaha, M. Cushman, S.R. Das, S. De Ferranti, J.P. Després, H.J. Fullerton, Heart disease and stroke statistics-2016 update a report from the American Heart Association, Circulation 133 (2016) e38-e48.
[4] H. Zhou, J. Wang, P. Zhu, H. Zhu, S. Toan, S. Hu, J. Ren, Y. Chen, NR4A1 aggravates the cardiac microvascular ischemia reperfusion injury through suppressing FUNDC1-mediated mitophagy and promoting Mff-required mitochondrial fission by CK2α, Basic research in cardiology 113 (2018) 23.
[5] H. Zhou, P. Zhu, J. Wang, H. Zhu, J. Ren, Y. Chen, Pathogenesis of cardiac ischemia reperfusion injury is associated with CK2α-disturbed mitochondrial homeostasis via suppression of FUNDC1-related mitophagy, Cell Death & Differentiation 25 (2018) 1080-1093.
[6] N. Hadebe, M. Cour, S. Lecour, The SAFE pathway for cardioprotection: is this a promising target?, Basic research in cardiology 113 (2018) 9.
[7] Y. Gao, Y.M. Zhang, L.J. Qian, M. Chu, J. Hong, D. Xu, ANO1 inhibits cardiac fibrosis after myocardial infarction via TGF-β/smad3 pathway, Scientific reports 7 (2017) 2355.
[8] L. Qian, J. Hong, Y. Zhang, M. Zhu, X. Wang, Y. Zhang, M. Chu, J. Yao, D. Xu, Downregulation of S100A4 Alleviates Cardiac Fibrosis via Wnt/β-Catenin Pathway in Mice, Cellular Physiology and Biochemistry 46 (2018) 2551-2560.
[9] R.J. Frost, E. van Rooij, miRNAs as therapeutic targets in ischemic heart disease, Journal of cardiovascular translational research 3 (2010) 280-289.

[10] S. Doroudgar, P. Quijada, M. Konstandin, K. Ilves, K. Broughton, F.G. Khalafalla, A. Casillas, K. Nguyen, N. Gude, H. Toko, S100A4 protects the myocardium against ischemic stress, Journal of molecular and cellular cardiology 100 (2016) 54-63.

[11] Y. Devaux, E.E. Creemers, R.A. Boon, S. Werfèl, T. Thum, S. Engelhardt, S. Dimmelé, I. Squire, C. Network, Circular RNAs in heart failure, European journal of heart failure 19 (2017) 701-709.

[12] Z.-w. Pan, Y.-j. Lu, B.-f. Yang, MicroRNAs: a novel class of potential therapeutic targets for cardiovascular diseases, Acta Pharmacologica Sinica 31 (2010) 1.

[13] Z. Hou, X. Qin, Y. Hu, X. Zhang, G. Li, J. Wu, J. Li, J. Sha, J. Chen, J. Xia, Longterm Exercise-Derived Exosomal miR-342-5p: A Novel Exerkine for Cardioprotection, Circulation research 124 (2019) 1386-1400.

[14] V. Kulasingam, E.P. Diamandis, Strategies for discovering novel cancer biomarkers through utilization of emerging technologies, Nature Reviews Clinical Oncology 5 (2008) 588.

[15] A. Keller, P. Leidinger, A. Bauer, A. ElSharawy, J. Haas, C. Backes, A. Wendeslag, N. Giese, C. Tjaden, K. Ott, Toward the blood-borne miRNome of human diseases, Nature methods 8 (2011) 841.

[16] A. Keller, P. Leidinger, B. Vogel, C. Backes, A. ElSharyawy, V. Galata, S.C. Mueller, S. Marquart, M.G. Schrauder, R. Strick, miRNAs can be generally associated with human pathologies as exemplified for miR-144, BMC medicine 12 (2014) 224.

[17] Z. Valenta, I. Mazura, M. Kolár, H. Grünfeldová, P. Feglarová, J. Peleška, M. Tomecková, J. Kalina, D. Slovák, J. Zvárová, Determinants of excess genetic risk of acute myocardial infarction-a matched case-control study, European Journal of Biomedical Informatics 8 (2012).

[18] C.B. Wiese, J. Zhong, Z.-Q. Xu, Y. Zhang, M.A.R. Solano, W. Zhu, M.F. Linton, Q. Sheng, V. Kon, K.C. Vickers, Dual inhibition of endothelial miR-92a-3p and miR-489-3p reduces renal injury-associated atherosclerosis, Atherosclerosis 282 (2019) 121-131.

[19] X. Zhou, Z. Qu, C. Zhu, Z. Lin, Y. Huo, X. Wang, J. Wang, B. Li, Identification of urinary microRNA biomarkers for detection of gentamicin-induced acute kidney injury in rats, Regulatory Toxicology and Pharmacology 78 (2016) 78-84.

[20] Q. Wei, Y. Liu, P. Liu, J. Hao, M. Liang, Q.-s. Mi, J.-K. Chen, Z. Dong, MicroRNA-489 induction by hypoxia–inducible factor–1 protects against ischemic kidney injury, Journal of the American Society of Nephrology 27 (2016) 2784-2796.

[21] G. Marot, J.-L. Foulley, C.-D. Mayer, F. Jaffrèzic, Moderated effect size and P-value combinations for microarray meta-analyses, Bioinformatics 25 (2009) 2692-2699.

[22] D. Szklarczyk, A. Franceschini, S. Wyder, K. Forslund, D. Heller, J. Huerta-Cepas, M. Simonovic, A. Roth, A. Santos, K.P. Tsafou, STRING v10: protein–protein interaction networks, integrated over the tree of life, Nucleic acids research 43 (2014) D447-D452.

[23] P. Shannon, A. Markiel, O. Ozier, N.S. Baliga, J.T. Wang, D. Ramage, N. Amin, B. Schwikowski, T. Ideker, Cytoscape: a software environment for integrated models of biomolecular interaction networks, Genome research 13 (2003) 2498-2504.

[24] T. Lehtimäki, T.A. Kunnas, K.M. Mattila, M. Perola, A. Penttilä, T. Koivula, P.J. Karhunen, Coronary artery wall atherosclerosis in relation to the estrogen receptor 1 gene polymorphism: an autopsy study, Journal of molecular medicine 80 (2002) 176-180.
[25] S. Mahmoodzadeh, J. Leber, X. Zhang, F. Jaisser, S. Messaoudi, I. Morano, P.A. Furth, E. Dworatzek, V. Regitz-Zagrosek, Cardiomyocyte-specific estrogen receptor alpha increases angiogenesis, lymphangiogenesis and reduces fibrosis in the female mouse heart post-myocardial infarction, Journal of cell science & therapy 5 (2014) 153.

[26] P. Zhai, T.E. Eurell, P.S. Cooke, D.B. Lubahn, D.R. Gross, Myocardial ischemia-reperfusion injury in estrogen receptor-α knockout and wild-type mice, American Journal of Physiology-Heart and Circulatory Physiology 278 (2000) H1640-H1647.

[27] E.A. Booth, N.R. Obeid, B.R. Lucchesi, Activation of estrogen receptor-α protects the in vivo rabbit heart from ischemia-reperfusion injury, American Journal of Physiology-Heart and Circulatory Physiology 289 (2005) H2039-H2047.

[28] M. Wang, P. Crisostomo, G.M. Wairiuko, D.R. Meldrum, Estrogen receptor-α mediates acute myocardial protection in females, American Journal of Physiology-Heart and Circulatory Physiology 290 (2006) H2204-H2209.

[29] A. Binder, A. Ali, R. Chawla, H.A. Aziz, A. Abbate, I.S. Jovin, Myocardial protection from ischemia-reperfusion injury post coronary revascularization, Expert review of cardiovascular therapy 13 (2015) 1045-1057.

[30] Y. Leng, Y. Wu, S. Lei, B. Zhou, Z. Qiu, K. Wang, Z. Xia, Inhibition of HDAC6 activity alleviates myocardial ischemia/reperfusion injury in diabetic rats: potential role of peroxiredoxin 1 acetylation and redox regulation, Oxidative medicine and cellular longevity 2018 (2018).

[31] S. Mu, T. Shimosawa, S. Ogura, H. Wang, Y. Uetake, F. Kawakami-Mori, T. Marumo, Y. Yatomi, D.S. Geller, H. Tanaka, Epigenetic modulation of the renal β-adrenergic–WNK4 pathway in salt-sensitive hypertension, Nature medicine 17 (2011) 573.

[32] R.D. Machado, O. Eickelberg, C.G. Elliott, M.W. Geraci, M. Hanaoka, J.E. Loyd, J.H. Newman, J.A. Phillips, F. Soubrier, R.C. Trembath, Genetics and genomics of pulmonary arterial hypertension, Journal of the American College of Cardiology 54 (2009) S32-S42.

[33] H.-A. Lee, D.-Y. Lee, H.-M. Cho, S.-Y. Kim, Y. Iwasaki, I.K. Kim, Histone deacetylase inhibition attenuates transcriptional activity of mineralocorticoid receptor through its acetylation and prevents development of hypertension, Circulation research 112 (2013) 1004-1012.

[34] Q. Yang, Z. Lu, R. Ramchandran, L.D. Longo, J.U. Raj, Pulmonary artery smooth muscle cell proliferation and migration in fetal lambs acclimatized to high-altitude long-term hypoxia: role of histone acetylation, American Journal of Physiology-Lung Cellular and Molecular Physiology 303 (2012) L1001-L1010.

[35] M.A. Thal, P. Krishnamurthy, A.R. Mackie, E. Hoxha, E. Lambers, S. Verma, V. Ramirez, G. Qin, D.W. Losordo, R. Kishore, Enhanced angiogenic and cardiomyocyte differentiation capacity of epigenetically reprogrammed mouse and human endothelial progenitor cells augments their efficacy for ischemic myocardial repair, Circulation research 111 (2012) 180-190.

[36] T. Azechi, D. Kanehira, T. Kobayashi, R. Sudo, A. Nishimura, F. Sato, H. Wachi, Trichostatin A, an HDAC class I/II inhibitor, promotes Pi-induced vascular calcification via up-regulation of the expression of alkaline phosphatase, Journal of atherosclerosis and thrombosis (2013) 15826.

[37] M. Xie, J.A. Hill, HDAC-dependent ventricular remodeling, Trends in cardiovascular medicine 23 (2013) 229-235.

[38] Y. Zhuang, J.Q. Mao, M. Yu, L.Y. Dong, Y.L. Fan, Z.Q. Lv, M.D. Xiao, Z.x. Yuan, Hyperlipidemia induces vascular smooth muscle cell proliferation involving Wnt/β-catenin signaling, Cell biology international 40 (2016) 121-130.
[39] H. Quasnichka, S.C. Slater, C.A. Beeching, M. Boehm, G.B. Sala-Newby, S.J. George, Regulation of smooth muscle cell proliferation by β-catenin/T-cell factor signaling involves modulation of cyclin D1 and p21 expression, Circulation research 99 (2006) 1329-1337.

[40] S. Kaga, L. Zhan, E. Altaf, N. Maulik, Glycogen synthase kinase-3β/β-catenin promotes angiogenic and anti-apoptotic signaling through the induction of VEGF, Bcl-2 and survivin expression in rat ischemic preconditioned myocardium, Journal of molecular and cellular cardiology 40 (2006) 138-147.

[41] Y. Morishita, K. Kobayashi, E. Klyachko, K. Jujo, K. Maeda, D.W. Losordo, T. Murohara, Wnt11 Gene Therapy with adeno-associated virus 9 improves recovery from myocardial infarction by modulating the inflammatory response, Scientific reports 6 (2016) 21705.

[42] Q. Li, S. Wu, S.-Y. Li, F.L. Lopez, M. Du, J. Kajstura, P. Anversa, J. Ren, Cardiac-specific overexpression of insulin-like growth factor 1 attenuates aging-associated cardiac diastolic contractile dysfunction and protein damage, American Journal of Physiology-Heart and Circulatory Physiology 292 (2007) H1398-H1403.

[43] O. Bourron, Y. Le Bouc, L. Berard, S. Kotti, N. Brunel, B. Ritz, F. Leclercq, X. Tabone, E. Drouet, G. Mulak, Impact of age-adjusted insulin-like growth factor 1 on major cardiovascular events after acute myocardial infarction: results from the fast-MI registry, The Journal of Clinical Endocrinology & Metabolism 100 (2015) 1879-1886.

[44] A. Kotlyar, Z. Vered, I. Goldberg, P. Chouraqui, D. Nas, E. Fridman, Z. Chen-Levy, S. Fytlovich, G. Sangiorgi, L. Spagnoli, Insulin-like growth factor I and II preserve myocardial structure in postinfarct swine, Heart 86 (2001) 693-700.
Figure legends:

Figure 1. Results of bioinformatics analysis. (A) Visualization of the PPI network. Different colors distinguish between upregulated and downregulated genes. Red nodes are highly expressed genes, while purple nodes are poorly expressed genes. (B) The new DEmiRNA-DEGs crosstalk network. The red circle represents the upregulated DEGs, the purple circle represents the downregulated DEGs, the green rectangle represents downregulated DEmiRNAs, and the red rectangle represents upregulated DEmiRNAs.

Figure 2. H₂O₂ induces H9c2 cell injury and miR-489 is upregulated in H₂O₂-induced H9c2 cardiomyocyte injury. (A) Cell viability was measured by Cell Counting Kit-8 assays after 0, 100, 200, 400, 450, and 500 μM hydrogen peroxide (H₂O₂) treatment for 1 h. (B) Expression of apoptosis-associated proteins as detected by Western blot analysis. (C) The miR-489 level was detected by RT-qPCR. The data are presented are the means ± standard error of the mean (SEM). (*P<0.05 vs. control; #P< 0.05 vs. H₂O₂).

Figure 3. MiR-489 overexpression increases cell apoptosis, while miR-489 inhibition decreases cell apoptosis in H₂O₂-treated H9c2 cells. (A) The miR-489 levels were evaluated by RT-qPCR. (B) Cell apoptosis was assessed by TUNEL assay (C) Cell apoptosis was evaluated by flow cytometry. (D) Expression of apoptosis-associated proteins was analyzed by Western blot analysis. The data are presented are
the means ± standard error of the mean (SEM). (*P<0.05 vs. control; #P< 0.05 vs. H₂O₂).

**Figure 4. IGF1 is a target of miR-489.** (A) Schematic diagram illustrating the wild-type (wt) and mutant (mut) 3’-UTR of IGF1 and the corresponding sequence of miR-489. (B) H9c2 cardiomyocytes were cotransfected with IGF1-WT or IGF1-Mut and miR-489 mimics or control, after which luciferase activity was assessed using a dual luciferase reporter assay. (C) The IGF1 protein levels in cardiomyocytes transfected with miR-489 inhibitor or mimics were detected by Western blot analysis. The data are presented are the means ± standard error of the mean (SEM). (*P<0.05 vs. control; #P< 0.05 vs. H₂O₂).
Figure 4
### 1. Supplementary Table S1

| DEmRNA       | logFC | P-Value  | Regulation |
|--------------|-------|----------|------------|
| GPR15        | 3.749676 | 0.017852 | up         |
| PRPH2        | 3.563579 | 0.003483 | up         |
| ZNF460       | -3.23099 | 0.030764 | down       |
| LOC102723377 | -3.19464 | 0.000455 | down       |
| ABCB8        | 3.189761 | 0.000342 | up         |
| LOC105371307 | -3.15007 | 0.00858  | down       |
| RNU6ATAC     | -3.13955 | 0.001746 | down       |
| C1orf140     | -3.08966 | 0.001683 | down       |
| SALL4        | -3.08893 | 0.002086 | down       |
| BRINP3       | 3.082552 | 0.005634 | up         |

### 2. Supplementary Table S2

| DEmiRNA       | ES     | P-Value     | FDR        | Regulation |
|--------------|--------|-------------|------------|------------|
| hsa-miR-1274b | -6.10032 | 1.06E-09 | 2.24E-07 | Down       |
| hsa-miR-142-3p | -6.13024 | 8.77E-10 | 2.24E-07 | Down       |
| hsa-miR-375  | -6.62421 | 3.49E-11 | 2.96E-08 | Down       |
| hsa-miR-489  | 6.124342 | 9.11E-10 | 2.24E-07 | Up         |
3. Supplementary Table S3

| Term                                                                 | Count | P Value   |
|----------------------------------------------------------------------|-------|-----------|
| GO BP                                                                |       |           |
| signal transduction involved in regulation of gene expression       | 5     | 0.002734  |
| bleb assembly                                                       | 4     | 0.003299  |
| neuron development                                                  | 6     | 0.015292  |
| regulation of transcription, DNA-templated                         | 64    | 0.015715  |
| gamete generation                                                   | 4     | 0.015832  |
| positive regulation of transcription from RNA polymerase II promoter| 44    | 0.02219   |
| negative regulation of Wnt signaling pathway                       | 6     | 0.024837  |
| homophilic cell adhesion via plasma membrane adhesion molecules     | 11    | 0.030713  |
| positive regulation of DNA replication                             | 5     | 0.044464  |
| GO CC                                                                |       |           |
| SAGA complex                                                        | 4     | 0.013182  |
| Golgi apparatus                                                     | 40    | 0.017885  |
| GO MF                                                                |       |           |
| histone acetyltransferase activity                                 | 6     | 0.017644  |
| nucleic acid binding                                               | 43    | 0.031575  |
| Cytokine-cytokine receptor interaction                             | 15    | 0.01294   |
| KEGG PATHWAY                                                        |       |           |
| Transcriptional misregulation in cancer                            | 11    | 0.026393  |
| Glycosphingolipid biosynthesis - lacto and neolacto series         | 4     | 0.040473  |
| Intestinal immune network for IgA production                       | 5     | 0.049705  |

Supplementary Table S1. The top ten differentially expressed genes.

Supplementary Table S2. Differentially expressed miRNAs.

Supplementary Table S3. Biological function and pathway analysis of DEGs.
**A**

IGF1

β-actin

Control  H₂O₂  H₂O₂+NC  H₂O₂+miR-489 inhibitor

**B**

5' UTR  IGF1 coding sequence  miR-489 binding site  3' UTR

WT IGF1 3' UTR: 5' GUGCUGUGUGUGUGUGUGUG

mio-miR-489: 3' CGACGUAUACAGUA

MUT IGF1 3' UTR: 5' GACGACAGUGUGUGUGUG

**C**

Relative Rluc/Luc ratio

|            | miRNA NC | miR-489 mimic |
|------------|----------|---------------|
| IGF1-WT    |          |               |
| IGF1-MUT   |          |               |